Physician profile
Orrin B Hansen
NPI 1104916543
$1,595.12
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $378 · 2023: $275 · 2024: $215 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.05 | 2021-2025 | |
| Pfizer INC. | $105.48 | 2021-2024 | |
| Lilly USA, LLC | $104.68 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Harmony Biosciences LLC | $85.00 | 2022-2025 | |
| Novo Nordisk INC | $75.20 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $65.99 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $61.60 | 2021-2025 | Capvaxive |
| Nestle Healthcare Nutrition INC. | $52.84 | 2021-2022 | |
| Amgen INC. | $48.64 | 2022-2025 | Evenity |
| Kowa Pharmaceuticals America, INC. | $44.81 | 2022-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.45 | 2022 | |
| Corcept Therapeutics | $41.96 | 2024-2025 | Korlym |
| Edwards Lifesciences Corporation | $41.78 | 2025 | Sapien 3 Ultra Resilia |
| Vertex Pharmaceuticals Incorporated | $28.14 | 2025 | |
| Axsome Therapeutics, INC. | $26.14 | 2024 | Sunosi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.43 | 2025 | Xifaxan |
| Daiichi Sankyo INC. | $24.23 | 2025 | Injectafer |
| Boston Scientific Corporation | $23.76 | 2025 | Watchman Access System |
| Dexcom, INC. | $20.01 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $19.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.30 | 2022 | |
| Kyowa Kirin, INC. | $19.07 | 2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $17.56 | 2021 | |
| Philips North America LLC | $16.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.51 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $14.66 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $14.43 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.79 | 2023 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orrin Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.